Reshaping the HIV treatment and prevention landscape

We have delivered 11 major approvals for new medicines or vaccines in the past four years Juluca dolutegravir 50 mg/ rilpivirine 25 mg tablets SHINGRIX HERPES ZOSTER VACCINE ONON-LIVE RECOMBINANT, ASO, ADRVANTED) TRELEGY VELLIPTA Kozenis (tafenoquine) Dovato dolutegravir/lamivudine 2H 2017 | 2018 *PRIMA FDA approval Apr 2020, TESARO acquisition Jan 2019 (first approval Mar 2017) 2019 ^TESARO asset BLENREP belantamab mafodotin-blmf for injection 100 mg Rukobia (fostemsavir) tablets-600mg extended-release ● Duvroq Zejula niraparib capsules 100 mg CABENUVA cabotegravir 200 mg/ml; rilpivirine 300 mg/mL extended-release injectable suspensions Jemperli (dostarlimab-gxly) Injection 500 mg 2020 | 1H 2021 Λ gsk 46

View entire presentation